Global Socioeconomic Impact of Cystic Echinococcosis by Budke, Christine M. et al.
Cystic echinococcosis (CE) is an emerging zoonotic
parasitic disease throughout the world. Human incidence
and livestock prevalence data of CE were gathered from
published literature and the Office International des
Epizooties databases. Disability-adjusted life years (DALYs)
and monetary losses, resulting from human and livestock
CE, were calculated from recorded human and livestock
cases. Alternative values, assuming substantial underre-
porting, are also reported. When no underreporting is
assumed, the estimated human burden of disease is
285,407 (95% confidence interval [CI] 218,515–366,133)
DALYs or an annual loss of US $193,529,740 (95% CI
$171,567,331–$217,773,513). When underreporting is
accounted for, this amount rises to 1,009,662 (95% CI
862,119–1,175,654) DALYs or US $763,980,979 (95% CI
$676,048,731–$857,982,275). An annual livestock produc-
tion loss of at least US $141,605,195 (95% CI
$101,011,553–$183,422,465) and possibly up to US
$2,190,132,464 (95% CI $1,572,373,055–$2,951,409,989)
is also estimated. This initial valuation demonstrates the
necessity for increased monitoring and global control of CE.
C
ystic echinococcosis (CE) is a condition of livestock
and humans that arises from eating infective eggs of
the cestode Echinococcus granulosus. Dogs are the pri-
mary definitive hosts for this parasite, with livestock acting
as intermediate hosts and humans as aberrant intermediate
hosts. The outcome of infection in livestock and humans is
cyst development in the liver, lungs, or other organ system.
The distribution of E. granulosus is considered worldwide,
with only a few areas such as Iceland, Ireland, and
Greenland believed to be free of autochthonous human CE.
However, CE is not evenly distributed geographically
(Figure 1) (1). For example, the United States has few
cases in livestock and most human cases are imported. The
same is true for regions of Western and Central Europe. In
many parts of the world, however, CE is considered an
emerging disease. For example, in the former Soviet Union
and Eastern Europe, the number of observed cases has dra-
matically increased in recent years (2–4). Additionally, in
other regions of the world, such as parts of China, the geo-
graphic distribution and extent of CE are greater than pre-
viously believed (5). CE not only causes severe disease and
possible death in humans, but also results in economic loss-
es from treatment costs, lost wages, and livestock-associat-
ed production losses. To date, no global estimates exist of
CE burden (total health, socioeconomic, and financial cost
of a given disease to society) in humans or livestock. Such
an estimate is imperative since it can be used as a tool to
prioritize control measures for CE, which is essentially a
preventable disease. 
Two methods previously used to assess disease burden
are disability adjusted life years (DALYs) and the calcula-
tion of monetary losses (6). DALYs were first developed in
the 1990s and were used in the Global Burden of Disease
(GBD) Study to determine the worldwide burden of disease
due to both communicable and noncommunicable causes
(7). Although the application of DALYs is becoming more
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Figure 1. Global distribution of zoonotic strains of Echinococcus
granulosus. (Adapted from Eckert and Deplazes, 2004 [1].
Copyright Institute für Parasitologie, Universität Zürich); used with
permission.commonplace, the use of DALYs and the methods behind
the creation of this measure remain debatable (8). The
GBD Study was an extensive undertaking; however,
echinococcosis was not among the conditions studied.
Nevertheless, DALYs have been applied to cystic
echinococcosis and alveolar echinococcosis, caused by
E. multilocularis, on a small scale in western China (9).
Likewise, monetary evaluations have been applied to CE
infections in humans and livestock only at a local level
(10–14). Global burden indicators not only give an idea of
the scope of the disease under study, but can also be used
to direct limited financial resources to sites where they can
be most effective. Because of the magnitude of applying
burden of disease measurements on a global scale, this
study must be considered a preliminary estimate.
Nevertheless, this report should increase awareness of the
global impact of CE by both the public health and live-
stock sectors. 
Materials and Methods
CE Incidence in Humans 
Data on country-specific annual reported human CE
cases were obtained from the Office International des
Epizooties (OIE), World Health Organization Handistatus
II database for the years 1996–2003 (15). This information
was then merged with published case reports from numer-
ous countries and logged into an Excel spreadsheet
(Microsoft Corp., Redmond, WA, USA). Type and quality
of incidence data varied by country or region; however,
most data consisted of annual numbers of detected cases
per susceptible population or was converted into this form
for analysis purposes. If both an OIE-reported and a liter-
ature-based value were available, the larger of the 2 was
used. However, if the higher value appeared to be from a
survey that evaluated a highly disease-endemic region and
was, therefore, not applicable to the entire country, a cor-
responding adjustment was made. In addition, we assumed
that ≈10% of annual cases are not officially diagnosed, and
those patients do not receive medical attention because of
their socioeconomic status or the subclinical nature of the
illness. Based on past studies, this estimate is most likely
conservative (12,14). For example, in China, mass ultra-
sound screening in remote areas has shown high preva-
lence rates of CE (9). A number of these patients have
advanced clinical disease but would not normally have
access to treatment because of poverty and distance from
medical facilities. Human cases of CE are also systemati-
cally underreported by the healthcare establishment, with
up to 75% of clinic or hospital-diagnosed cases never
recorded in local or national databases or published reports
(16,17). Therefore, adjustments were made to account for
the substantial underreporting of known treated cases.
CE Prevalence in Livestock
Numbers of annual reported CE cases in slaughtered
livestock (sheep, goats, cattle, camels, and swine) for the
years 1996–2003 were obtained from the OIE-Handistatus
II database (15). This information was merged with abat-
toir studies performed in numerous countries. If data from
both sources were available, the larger of the 2 estimates
was used. However, if the higher value appeared to be
from a region that was highly disease-endemic and was not
appropriate for a countrywide estimate, an adjustment was
made. Prevalence per species, for each country, was
applied to the estimated number of slaughtered animals per
year, with 2004 livestock numbers obtained from the FAO-
STAT database (18). The assumption was made that
approximately one fourth of sheep and goat populations,
one sixth of cattle and camel populations, and the entire
swine population would be slaughtered annually, based on
estimated average species’ lifespan (e.g., approximately
one fourth of a country’s sheep population would be
slaughtered annually, with a typical animal life expectancy
of 4 years). Such a general estimate was used because of
the large amount of variation in animal production prac-
tices between and within countries. As with the human
incidence data, the true number that were positive for E.
granulosus at slaughter is substantially higher than report-
ed. Therefore, a correction factor was used to estimate true
prevalence. 
Application of DALYs to Human Incidence Data
The DALY formula (shown below) was applied to
global human incidence data.
In this equation, D is a disability weight, β is an age-
weighting function parameter, C is an age-weighting cor-
rection constant, r is a discount rate, a is age at clinical
onset, and L is the duration of disability or time lost
because of death (7). Disability weight for CE was
assigned a multinomial distribution based on numerous
retrospective studies evaluating postoperative outcome
(Table 1) (19–24). The percentage of patients projected to
improve after surgery was assigned a disability weight of
0.200 (Dutch weight for clinically disease-free cancer) for
1 year, the percentage of patients projected to have sub-
stantial postsurgical conditions was assigned a disability of
0.239 (GBD weight for preterminal liver cancer) for 5
years, the percentage of patients projected to have recur-
rent disease was assigned a disability of 0.809 (GBD
weight for terminal liver cancer) for 5 years, and the per-
centage of patients projected to die postoperatively were
assigned a disability of 1 (indicating death) for the remain-
der of their predicted lifespan (7,25). An assumption was
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1 1 2also made that ≈10% of cases are not reported and do not
receive medical treatment. These cases were assigned a
disability weight of 0.200 (Dutch weight for clinically dis-
ease-free cancer) for 10 years (25). For the GBD Study, a
standardized life table was used for L (7). 
Economic Evaluation of Human-associated Losses
Overall cost per human surgical case was based on
findings from previous international studies (Table 2)
(11,13,14,26,27). Expenses taken into consideration
included diagnostic costs, surgical cost, hospitalization,
and postoperative costs. The average cost per surgical
patient was shown to be significantly correlated (R2 =
0.898, p < 0.05), with the country-specific per capita gross
national income (per capita GNI) (Atlas Method) (Table
2). Therefore, the linear regression coefficient was used as
a predictor of treatment costs for each disease-endemic
country. In addition to medical costs and single-year wage
losses, past studies have indicated an average 2.2% postop-
erative death rate for surgical patients (Table 1).
Approximately 6.5% of cases also are assumed to relapse
and require a prolonged recovery time (Table 1) (11).
Therefore, these outcomes were also taken into account.
We assumed that, in addition to surgical cases, ≈10% of
cases are not officially diagnosed each year, and those
patients never receive treatment. Wage losses for this
group were thus taken into consideration. Economic losses
in humans were also evaluated, taking into account the
nearly 4-fold degree of underreporting of patients who
received treatment.
Economic Evaluation of Livestock-associated Losses
Production-based losses attributable to infected sheep,
goats, cattle, camels, and pigs were estimated. Losses from
liver condemnation, defined as the action of preventing the
sale of livers deemed unfit for human consumption (sheep,
goats, cattle, pigs, camels), reduction in carcass weight
(sheep, goats, cattle), decrease in hide value (sheep, cattle),
decrease in milk production (sheep, goats, cattle), and
decreased fecundity (sheep, goats, cattle) were taken into
account. Only liver-associated losses in camels and pigs
are presented since few studies have evaluated production
losses from echinococcosis in these species (28). Losses
from liver condemnation are assumed to occur since hepat-
ic pathology is associated with infection in swine and
camels (29). Losses from liver condemnation were pre-
sumed proportional to those used for the analysis of the
economic impact of CE in Jordan (12). Decrease in hide
value (20%) and decrease in fecundity (11%) were pre-
sumed proportional to values suggested by numerous
Soviet studies conducted from the 1950s through the 1980s
(28). Reductions in carcass weight (2.5%) and milk pro-
duction (2.5%) were also based on previous reports (30). 
Analysis
Spreadsheet models were constructed in Excel to esti-
mate global impact of CE in terms of DALYs and mone-
tary losses. Total disease effects, in DALYs lost or
monetary costs, was calculated by summing all of the con-
stituent components. Uncertainty in parameter estimates
was modeled by using Monte Carlo techniques (6). Briefly,
all parameters were assigned a probability distribution
based on the quantity and quality of reported data. Macros
were written in Excel to sample across these distributions,
with 10,000 iterations of each model calculated. Mean and
95% confidence intervals (CIs) for losses were then deter-
mined from these iterations.
Reported global human incidence was assigned a nor-
mal distribution, with a standard deviation of 5%.
Adjustments were then made to account for the nearly 4-
fold degree of underreporting of treated cases believed to
occur (16,17). In addition, cases that would not be official-
RESEARCH
298 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 12, No. 2, February 2006ly acknowledged had to be accounted for, i.e., cases in per-
sons who never receive treatment in a hospital. We there-
fore assumed that ≈10% (uniform distribution of 8% to
12%) of cases would not be detected. This estimate is con-
servative compared to other country-specific estimates
(12,14).
The DALYformula was applied to worldwide CE cases
in a stochastic manner similar to that used to apply DALYs
to echinococcosis cases in a region of western China (10).
Mean age of clinical onset (a) was allocated a uniform dis-
tribution of 30 to 40 years, established on the basis of var-
ious studies (Table 3) (4,9,21,31–34). Numerous and
varying reports have indicated the sex of CE-positive per-
sons with women tending to be infected at a higher rate
than men. Based on these reports, we assigned a uniform
distribution of 50% to 60% of infected persons as female
(4,35). Number of DALYs lost, using incidence values cor-
rected and uncorrected for underreporting of surgical inci-
dence, was determined. 
Human-associated economic losses were applied in a
stochastic manner similar to that used for a region of
western China (10). Variability in surgical treatment
costs, due to CE, was modeled by using a uniform distri-
bution of 50% to 90% of per capita GNI per country and
was weighted by each country’s contribution to global
human CE incidence (36). Lower income, higher unem-
ployment, or both has been associated with a diagnosis of
CE (4,10). Consequently, a decrease in wages earned was
assumed, at least for the year of initial diagnosis and
treatment. Therefore, all patients were assigned a uniform
loss of 50% to 90% of country-specific per capita GNI for
1 year (36). Approximately 6.5% of patients were also
assigned a 50%–90% wage loss for 4 additional years
because of relapse and prolonged recovery time. In addi-
tion, 2.2% of patients were assigned a 100% wage loss
until the expected retirement age of 65 due to postsurgi-
cal death. A standard 3% discounting rate was applied to
all income losses (7). In addition to surgical cases, ≈10%
of cases (uniform distribution of 8% to 12%) annually
were assumed to not be officially diagnosed. A25% wage
loss for 5 years was consequently assigned to this popula-
tion. This estimate is conservative and does not take into
account income losses attributable to undiagnosed cases
with fatal outcomes. Projections were made that assumed
the absence and presence of underreporting of surgical
incidence (16,17). In addition to using real per capita GNI
(Atlas Method), calculations were also performed by
using purchasing power parity (ppp) adjusted per capita
GNI.
As with human-associated economic losses, livestock-
associated losses were applied in a stochastic manner (10).
Livestock prices were given uniform distributions of US
$30–$60 for sheep, US $15–$30 for goats, US $150–$350
for cattle, US $300–$600 for camels, and US $55–$75 for
pigs. Uniform distributions were used because of the large
regional variations in prices and assigned in accordance
with baseline prices for most affected countries.
Production losses were assumed to follow a log-normal
distribution; most affected animals were lightly infected,
and only a small proportion of animals had severe losses.
As with human cases, substantial underreporting of live-
stock infection was recognized, since official reporting is
not mandatory in most countries. Therefore, a uniform cor-
rection factor of 1.5 to 2 was used to approximate true eco-
nomic losses. A large uniform distribution was used
because of the lack of information concerning true global
prevalence of CE in livestock. This lack will, therefore, be
represented in the wide confidence limits obtained. 
Results
DALYs
Regional findings for predicted global burden of CE in
terms of DALYs lost, with 95% CIs, can be found in
Table 4. The most conservative estimate of number of
global DALYs lost is 285,407 (95% CI 218,515–366,133),
with no consideration for disease underreporting.
Estimated number of global DALYs lost, taking into con-
sideration nonreported surgical cases, is 1,009,662 (95%
CI 862,119–1,175,654).
Human-associated Economic Losses
Findings for predicted regional burden of human CE in
economic terms, with 95% CI, can be found in Table 5.
Global losses, assuming no underreporting, are estimated at
US $193,529,740 (95% CI $171,567,331–$217,773,513).
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$763,980,979 (95% CI $676,048,731–$857,982,275).
When ppp adjusted per capita GNI is used instead of real
per capita GNI, estimated annual overall losses, without
correction for underreporting, are US $484,878,359 (95%
CI $432,898,134–US $542,048,125). When corrected for
underreporting, annual losses are estimated at US
$1,918,318,955 (95% CI $1,700,574,632–$2,142,268,992)
(Table 5). 
Livestock-associated Economic Losses
Estimated livestock-associated losses, with 95% CI,
can be found in Table 6. Minimal annual losses, assuming
liver condemnation alone with no correction for underre-
porting, is estimated at US $141,605,195 (95% CI
$101,011,553–$183,422,465). However, when losses from
additional production factors (decreased carcass weight,
decreased milk production, decreased hide value,
decreased fecundity) are taken into account, losses range
from US $1,249,866,660 (95% CI $942,356,157–$1,622,
045,957), not taking into account underreporting, up to US
$2,190,132,464 (95% CI $1,572,373,055–$2,951,409,
989), when underreporting is considered.
Discussion
Even without correcting for the underreporting of
human and livestock cases, CE has a substantial global dis-
ease impact in terms of DALYs and monetary losses. The
importance of using both indicators is illustrated by the
proportional difference in DALYS lost versus economic
losses per region (Tables 4 and 5). If only monetary losses
were evaluated, the severity of the situation in poorer
regions would be underestimated because of the decreased
income and economic value of livestock products relative
to more economically prosperous regions. For example,
China is responsible for 40% of the world’s CE DALYs but
only 19% of human-associated economic losses. However,
losses based on ppp-adjusted per capita GNI give a better
picture of the relative distribution of disease impact (Table
5). When the number of DALYs lost, taking into account
the recognized underreporting of human cases, is com-
pared with those of other parasitic conditions evaluated by
the World Health Organization (WHO), worldwide losses
due to CE are slightly less than those caused by African
trypanosomiasis (1,525,000) and more than  those caused
by onchocerciasis (484,000) or Chagas disease (667,000)
(37). Even though estimated number of DALYs lost from
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of the tropical disease cluster, CE continues to be exclud-
ed from funding associated with conditions related to low
socioeconomic status. This exclusion best illustrated by
evaluating research and training funding provided by the
United Nations Children’s Fund (UNICEF)/United
Nations Development Programme (UNCP)/World Bank/
WHO-supported Special Programme for Research and
Training in Tropical Diseases (TDR). If funding for CE
were placed on the same scale as TDR-supported diseases,
based on estimated DALYs lost, CE should receive
approximately US $1,200,000 annually (Figure 2) (38).
For now, however, CE continues to be widely underappre-
ciated by most international agencies. These findings
emphasize the need for CE to be taken seriously as a glob-
al public health condition, regardless of its economic
implications. What makes this disease exceptional, howev-
er, is that it is not only a substantial human health problem
but also has a considerable economic effect on the live-
stock industries of some of the most socioeconomically
fragile countries.
In addition to reporting the estimated global burden of
CE, this study has shown the need for more accurate
reporting of infected humans and livestock. Very few
country-specific estimations of the true incidence of CE in
humans have been made and no studies, to the authors’
knowledge, that estimate its true prevalence in livestock
(16,17). Presentation of the substantial economic losses for
both the public health and agricultural sectors will also, we
hope, encourage countries and international organizations
to more closely examine potential control programs and
cost-sharing methods between the 2 affected sectors (10). 
The values presented in this paper are not definitive but
instead estimates of the severity of the global situation
from human- and livestock-associated CE. Considerable
sums of money have been invested in the investigation and
control of such parasitic conditions as lymphatic filariasis
and onchocerciasis. Although these conditions can result in
severe human disease, unlike CE they do not have severe
secondary economic implications, such as massive live-
stock production losses (39,40). In addition, regional con-
trol programs that have been implemented and
recommended thus far for CE, based on combinations of
dog deworming, stray dog culling, sheep and goat vaccina-
tion, and education programs, have been shown to be very
cost effective (10,27). CE is, therefore, a worthy condition
for research and control program implementation, with
substantial anticipated return on invested funding.
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